This webcast features: Dr. Linda Pullan, Founder, Pullan Consulting
China’s biopharmaceutical industry is continuing its growth momentum. This robust growth is boosted by continuous investment into the sector. A clear strategic indicator of the government’s intentions in biopharma and biologics has been the China’s investment in biopharma industrial hubs, which will have added more than USD $300 billion to the biological industry nationwide by 2020. In Part 2 of our series, Dr. Linda Pullan, Principal, Pullan Consulting, covers China investments, as well as advice for negotiating China deals.
Just fill out the form below to watch the recorded webcast now.